This is an HTML version of an attachment to the Freedom of Information request 'EFPIA and DG Trade'.





Ref. Ares(2022)3545646 - 10/05/2022
From: 
Art. 4.1(b)
 (CAB-DOMBROVSKIS) 
Sent: 
vendredi 6 août 2021 18:06 
To: 
CAB DOMBROVSKIS ARCHIVES;  Art. 4.1(b)
 (CAB-DOMBROVSKIS); 
Art. 4.1(b)
 (CAB-DOMBROVSKIS); 
Art. 4.1(b)
(CAB-DOMBROVSKIS);  Art. 4.1(b)  (CAB-DOMBROVSKIS) 
Subject: 
FW: Kind request for a meeting with Executive Vice President 
Dombrovskis 
To register 
Yes, would be in favour 
From: 
Art. 4.1(b)
Sent: Friday, August 6, 2021 3:39 PM 
To: 
 (CAB-DOMBROVSKIS) 
Art. 4.1(b)
Cc: 
 (CAB-DOMBROVSKIS) 
Art. 4.1(b)

 (CAB-DOMBROVSKIS) 

; Leadership-team 
Subject: Kind request for a meeting with Executive Vice President Dombrovskis 
Dear  Art. 4.1(b) , 
On behalf of the innovative pharmaceutical industry represented by EFPIA, I would like 
to kindly request a meeting for a delegation of our Board members with Executive Vice 
President Dombrovskis in the coming months.  
There are several areas that our Board would welcome an opportunity to discuss with the 
Executive Vice President, among which the following: 
- the ongoing discussions in the area of pharmaceuticals as they relate to the ongoing
EU/New Zealand FTA negotiations
- the opportunity of setting up a business dialogue in the margins of the EU/US Trade and
Technology Council
- the ongoing WTO discussions on IP and COVID-related healthcare technologies
- Medicines and the implementation of the protocol on Ireland and Northern Ireland
Thank you in advance for your consideration and we very much hope that it will be 
possible to organise such a meeting in the coming months. 
I look forward to hearing from you and am at your disposal for any additional 
information you might need. 
Best wishes, 
Art. 4.1(b)
Art. 4.1(b)


Director General
EFPIA - European Federation of Pharmaceutical Industries and Associations
Leopold Plaza Building 
Rue du Trône 108 
B-1050 Bruxelles
Tel:  Art. 4.1(b)
(Direct Line)
Tel: +3226262555 (Switchboard)
Email:  Art. 4.1(b)
www.efpia.eu 
For more information related to COVID-19 see: https://efpia.eu/news-
events/the-efpia-view/statements-press-releases/european-pharmaceutical-
industry-response-to-coronavirus/